VISTAGEN THERAPEUTICS, INC. Deferred Offering Costs
VISTAGEN THERAPEUTICS, INC. (VTGN) had Deferred Offering Costs of $224.70 thousand as of 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2021-08-12
- 2021-06-30: Deferred Offering Costs $224.70K.
- 2021-03-31: Deferred Offering Costs $294.90K.
- 2020-12-31: Deferred Offering Costs $241.30K.
- 2020-09-30: Deferred Offering Costs $268.50K.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-06-30 | $224.70K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $294.90K 10-Q · filed 2021-08-12 |
| 2020-12-31 | $241.30K 10-Q · filed 2021-02-11 |
| 2020-09-30 | $268.50K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $263.90K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $355.10K 10-K · filed 2021-06-29 |
| 2019-03-31 | $22.30K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |